Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin
Open Access
- 1 October 1984
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 26 (4), 466-475
- https://doi.org/10.1128/aac.26.4.466
Abstract
The antiviral effects of selenazofurin (2-beta-D-ribofuranosylselenazole-4-carboxamide, selenazole), ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), and 3-deazaguanosine (6-amino-1-beta-D-ribofuranosylimidazo-[4.5-C]pyridin-4(5H)-one) were investigated separately and in various combinations in an in vitro study. The combination interactions were evaluated at seven drug concentrations, graphically (isobolograms) or by using fractional inhibitory concentration indices against mumps, measles, parainfluenza virus type 3, vaccinia and herpes simplex virus type 2 viruses in Vero and HeLa cells. Selenazofurin in combination with ribavirin produced the greatest synergistic antiviral activity. However, the degree of synergy depended on the virus and cell line used. In contrast, selenazofurin combined with 3-deazaguanosine consistently yielded an indifferent or an antagonistic response, or both, whereas the ribavirin-3-deazaguanosine interaction was additive against the same viruses. Single-drug cytotoxicity was minimal for the cytostatic agents selenazofurin and ribavirin but was markedly higher for cytocidal 3-deazaguanosine, as determined by relative plating efficiency after drug exposure. The drug combinations did not significantly increase cytotoxicity (they were only additive) when used on uninfected cells. Therefore, the enhanced antiviral activities of the drug combinations (shown to be synergistic) were due to specific effects against viral replication. These results indicated that in Vero and HeLa cells (i) the combination of selenazofurin and ribavirin produced an enhanced antiviral effect, thus requiring smaller amounts of drug to cause the same antiviral effect relative to a single compound; (ii) selenazofurin when compared with ribavirin and 3-deazaguanosine appeared to have a somewhat different mode of antiviral action; (iii) 3-deazaguanosine combined with selenazofurin was an unsuitable antiviral combination; and (iv) the antiviral activity of 3-deazaguanosine appeared to be due largely to its general overall cytotoxic effect.This publication has 48 references indexed in Scilit:
- Comparative invitro studies of tiazofurin and a selenazole analogBiochemical and Biophysical Research Communications, 1983
- Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-β-D-ribofuranosylselenazole-4-carboxamideBiochemical and Biophysical Research Communications, 1983
- Conversion of 2-β-D-ribofuranosylselenazole-4-carboxamide to an analogue of nad with potent imp dehydrogenase-inhibitory propertiesBiochemical Pharmacology, 1983
- The broad spectrum antiviral agent ribavirin inhibits capping of mRNABiochemical and Biophysical Research Communications, 1979
- Combined action of ribovirin and rimantadine in experimental myxovirus infectionCellular and Molecular Life Sciences, 1977
- THE SELECTIVE INHIBITION OF VIRAL DNA SYNTHESIS BY CHEMOTHERAPEUTIC AGENTS: AN INDICATOR OF CLINICAL USEFULNESS? *Annals of the New York Academy of Sciences, 1977
- Inhibition of influenza RNA synthesis by virazole (ribavirin)Archiv für die gesamte Virusforschung, 1976
- Inhibition of the Replication of Influenza A and B Viruses by a Nucleoside Analogue (Ribavirin)Journal of General Virology, 1975
- Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesisLife Sciences, 1975
- Combination chemotherapy: The antagonism of methotrexate and cytosine arabinosideEuropean Journal of Cancer (1965), 1973